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Abstract
The specificity and affinity of self-reactive T cells is likely to impact the development of autoimmune-disease causing T cells
in the thymus as well as their function in the periphery. We identified a naturally occurring, low affinity variant of an MBP
Ac1-11/I-A
u specific TCR that is known to induce EAE. Thymocytes in mice carrying the transgenes for this low affinity TCR
were poorly positively selected, as compared to their high affinity TCR expressing counterparts. Nonetheless, CD4 T cells
bearing the low affinity TCR accumulated in the periphery of the mice. Unlike mice expressing the high affinity TCR, these
mice very rarely developed disease. However, if endogenous TCR expression was eliminated by breeding to RAG1 deficient
mice, 100% of the mice carrying either the high or the low affinity versions of the TCR developed EAE. Intriguingly, while the
incidence of EAE increased, the age of onset of disease in both mice was identical. These data suggest disease onset occurs
during a short window of mouse development.
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Introduction
Developing T cells require a functional interaction between the
TCR and self-MHC:self-peptide complexes [1,2]. In general, it is
thought that low affinity interactions lead to maturation, whereas
high affinity interactions result in clonal deletion. These
complementary selection processes lead to the development of a
self-referential T cell repertoire that is both tolerant to self, yet
sufficiently diverse to respond to pathogenic challenges [3,4,5,6,7].
Data suggests that in addition to defining positive versus negative
selection, TCR affinity for selecting ligands may also play an
instructive role in defining lineage commitment. For example, high
affinity interactions have been suggested to direct developing
thymocytes towards functionally distinct lineages such Treg,
iNKT, CD8aa and Ly6C
+ T cells [1,8,9]. Additionally,
commitment to the conventional CD4 and CD8 lineages may
also be influenced by TCR affinity [10].
EAE is an inflammatory, demyelinating disease manifested by
acute, chronic or relapsing paralysis [11], similar to human
multiple sclerosis [12]. The disease is mediated primarily by MHC
class II-restricted CD4
+ T cells that secrete inflammatory cytokines
[11]. Stimulation of anti-inflammatory Th2 T cells that secrete IL-
4 and IL-10, however, has been shown to inhibit EAE [13]. To
determine if TCR affinity influences the onset of EAE, we
identified and cloned a TCR that has considerably lower affinity
for the Ac1-11 MBP peptide presented by I-A
u as compared to a
previously published TCR [14]. Transgenic mice expressing this
new low affinity TCR were generated and compared to an existing
high affinity TCR transgenic mouse.
On a wild type B10.PL background, the incidence of
spontaneous disease initiated by T cells expressing the low affinity
TCR was very low, as compared to the high affinity TCR
transgenic mouse. When bred to a RAG1 deficient background,
which is known to increase the frequency of EAE, at least in part
due to the loss of residual CD4
+CD25
+ Tregs [15,16,17], both the
high and low affinity TCRs induced the onset of EAE in 100% of
mice. Intriguingly, the age of onset of disease in mice with and
without Tregs was nearly identical.
Materials and Methods
Animals
All animal work was done in compliance with Memorial Sloan-
Kettering Cancer Center’s Internal Animal Care and Use
Committee (IACUC) and the guidelines of the Federal Office
of Laboratory Animal Welfare. The approved protocol number
was 05-03-005. Mice were housed and bred in specific pathogen-
free environments in microisolators in the Research Animal
Resources Center (RARC) of Memorial Sloan-Kettering Cancer
Center (MSKCC). Additional mice were purchased from The
Jackson Laboratory. Animal housing rooms were under temper-
ature and humidity control, the mice were not subjected to water
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cage. Four full time veterinarians and six veterinarian technicians
staff the facility. The veterinary staff is located on site and a
clinical veterinarian is available at all times. Animal care staff
carried out routine husbandry procedures including changing
cages, feeding and watering. All mice were sacrificed prior to use.
Euthanasia was conducted in accordance with the American
Veterinary Medical Association (AVMA) Guidelines on Eutha-
nasia. Briefly, mice were sacrificed by asphyxiation with CO2.
CO2 is delivered into the cages at less than 5psi per second.
Death of the animal is confirmed by lack of respiration and toe
pinch. CO2 euthanasia stations are inspected regularly by
IACUC personnel. After confirmation of death, tissues were
removed for experiments. In studies involving the incidence of
spontaneous EAE, mice were examined at least three times per
week for evidence of disease. Histological analysis confirmed
pathological lesions associated with EAE in hindlimb-paralyzed
mice (data not shown). Of note were mononuclear cell
accumulations in the perivascular, meningeal and parenchymal
regions of the brain.
Hybridomas
TCR Va2 depleted or total T cells (see results section) were
activated and fused to BW5147 cells as previously described [18].
Fused cells were plated at a density likely to generate clonal
populations. In addition, hybridomas used for assays were cloned
by limiting dilution and analyzed by FACS for TCR and CD4
expression. Stimulation assays were carried out as previously
described [18].
TCRa transgene
cDNA made from the hybridomas was screened with a panel
of 24 Va specific primers that we generated based on published
sequences [19]. The primers were tested by amplifying cDNA
generated from mRNA from wild type thymocytes RNA. PCR
products were cloned (TOPO TA, Invitrogen) and sequenced.
Based on this information, PCR primers were designed to amplify
genomic DNA from one of the Va6 hybridomas from 59 of the
ATG to 150 bp 39 of the end of the Ja segment (within the Ja-Ca
intron). This DNA fragment was cloned, sequenced and then
transferred into the paTris vector [20]. The purified transgene
was injected into fertilized F1 eggs obtained by mating B10.PL
and C57Bl/6 mice. Transgene positive founders were back-
crossed to B10.PL and typed to confirm homozygous expression
of I-A
u. Two different founder lines were established. Data from
the two founder mouse lines (FACS, onset of EAE, etc.) was
nearly identical and, therefore, only one founder was fully
analyzed.
T Cell Proliferation Assays
Lymph nodes and spleens from healthy 6-8 week-old MBPab
TCR and OVab TCR transgenic mice were harvested. Magnetic
depletion (BioMag beads; PerSeptive Biosystems, Framingham,
MA) using antibodies against MHC class II, CD8, Mac1 and
NK1.1 was used to enrich for CD4
+ T cells. Cell purity (typically
.90%) was checked by FACS with antibodies against CD4 and
TCR Vb8. APCs were prepared by incubation of single-cell
suspensions of B10.PL splenocytes with antibodies against CD4,
CD8, and Thy 1 followed by incubation with rabbit complement
and mitomycin C for 30 min at 37uC. Experiments were set up in
triplicate in 96-well, round-bottom plates with 2.5610
4 T cells
(total cell number adjusted based upon purity) and 1610
5 APCs.
Assays were pulsed with 0.5 mCi per well of [3H]thymidine after
48 hours and were harvested after an additional 24 hours.
Blocking assays were carried out as previously published [21].
No T cell proliferation is induced by the F23.1 antibody at the
doses that were used.
Tissue preparation and FACS Analysis
Single-cell suspensions were prepared by dissociation of tissues
between glass slides. To block nonspecific antibody binding, cells
were first incubated for 15 minutes with anti-mouse FC-RIII
antibody and normal mouse serum (Jackson Labs). Cells were
washed and then stained for 30 minutes with the appropriate
cocktail of the following antibodies from BD Biosciences: CD4-
PerCP-Cy5.5, CD8-APC, Vb8 FITC, Va2-PE, CD69-PerCP-
Cy5.5, CD44-FITC, CD25-PE, CD62L-APC and TCRCa-APC.
Cells were washed and analyzed on a Becton Dickinson LSR or
DakoCytomation Cyan.
Cell sorting
Cell sorts were done in MSKCC’s Flow Cytometry Core
Facility on a DakoCytomation MoFlo. Sorted populations were
reanalyzed and proved to be over 98% pure.
Results
Identification of a low affinity TCR
Mice carrying the transgenes for a MBP AC1-11 peptide
specific TCR (Va2.3-Ja11; Vb8.2-Jb2.6) cloned from the 172.10
hybridoma have been described [14]. T cells from these TCR
transgenic mice respond strongly to the Ac1-11 myelin basic
protein (Ac1-11) peptide bound to I-A
u and these mice
spontaneously develop EAE (1, 9). Previously, we have shown
that mice carrying only the TCRb transgene (MBPb TCR) are
highly enriched (approximately 0.01% of total CD4 SP thymo-
cytes) for T cells specific for the Ac1-11:I-A
u complex [22]. As a
result, in vitro culture of total lymph node cells taken from MBPb
TCR transgenic mice with the Ac1-11 peptide results in a strong,
dose-dependent T cell response. Other than the somewhat
restricted TCR repertoire, MBPb TCR transgenic mice are
indistinguishable from wild type mice since they have normal
numbers of both CD4 and CD8 T cells that express a diverse
TCR repertoire [22].
In an effort to identify T cells with a low affinity for the MBP
Ac1-11:I-A
u ligand, we harvested lymph node cells from MBPb
TCR transgenic mice and bulk cultured the cells with 10 mMo f
the peptide. After seven days, cells were analyzed by FACS using
mAbs against CD4, Vb8 and Va2. As expected, nearly all of the
surviving cells were CD4
+ (Fig. 1A) and expressed that the
transgene encoded Vb8
+ TCRb chain (Fig. 1A). Interestingly, in
six independent experiments, we consistently observed two
different T cell populations when we stained with an anti-Va2
mAb. Approximately 70% of the T cells were always found to be
Va2
+, while approximately 30% of the cells were Va2 negative
(Fig. 1A). This ,2:1 ratio was found with several different doses of
peptide and was stable if the T cells were activated several more
times (data not shown).
Our finding that the non-Va2 T cells were consistently a smaller
percentage of the total cultured T cell population suggested that
these cells might be expressing TCRs that were lower affinity as
compared to the Va2
+ cells. To test this, we sorted the two
populations from bulk cultured T cells that had gone through
several rounds of activation in vitro. The sorted T cells were
stimulated with titrated amounts of the Ac1-11 peptide presented
by T cell depleted, irradiated B10.PL spleen cells. As shown, in
Fig. 1B, the Va2
+ cells responded substantially better than their
Va2
2 counterparts. While the magnitude of the T cell response
TCR Affinity and EAE
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cell numbers used, the difference in the response between the two
T cell populations was consistent. Importantly, the anti-Va2 mAb
itself does not induce or block activation of T cells and, therefore,
is not a factor in these T cell assays [23].
In an effort to clone the TCRa chain or chains used by the
Va2
+ and Va2
2 populations, we generated T cell hybridomas
[18]. For our first fusion, we used T cells that had been bulk
cultured by feeding several times with irradiated B10.PL
splenocytes loaded with 10 mM Ac1-10 peptide. Prior to the final
activation, the bulk culture was split and magnetic beads were used
to deplete out the Va2
+ cells from one of the two cultures. Two
days after activation, the T cells were fused to BW5147 and plated
at a density likely to produce single cell clones [18]. The resulting
hybridomas were screened by FACS with mAbs against the TCRb
chain, Va2 and CD4. Specificity of the clones was confirmed by
carrying out T cells assays with Ac1-11 peptide loaded APCs.
Activated T hybridomas produced IL-2, which was detected by
the IL-2 dependent cell line, CTLL-2 (data not shown). Dose-
response assays confirmed that, similar to the sorted T cells, the
Va2
+ hybridomas responded much better to the Ac1-11 peptide
(data not shown).
Twenty Va2
+, CD4
+ clones and twenty Va2
2, CD4
2 clones
were selected and used for further studies. cDNA from the Va2
+
clones was PCR amplified with primers specific for Va2 and the
Ca gene segments. The amino acid sequences deduced from the
sequences of the PCR products were identical both to each other
and to the original Ac1-11/I-A
u specific 172.10 hybridoma. This
finding is consistent with our previous work in which we found that
positive selection in the thymus resulted in a repertoire that was
enriched for TCRs using the TCRa chain found in the original
172.10 T cell hybridoma [22].
The Va2
2 hybridomas were also negative for the three other
available anti-Va gene segment mAbs. Therefore, we screened the
clones by RT-PCR utilizing a panel of 24 different Va specific
primers that we designed to amplify all known mouse Va gene
segments. Other than the endogenous TCRa chain known to be
expressed by the BW5147 cell line, only one primer set
consistently resulted in a PCR product. We cloned and sequenced
the PCR fragment and found that all twenty hybridomas
expressed the identical TRAV6-7/DV9*02 - TRAJ13*01 (Va6-
Ja13) TCRa chain (Fig. 1C). Interestingly, other than a single
amino acid change in the CDR3a segment, the TCRa chain we
cloned is identical to a TCRa chain cloned from an AC1-9/I-Au
specific T cell derived from a wild type B10.PL mouse [24]. This
closely related TCR, however responds strongly to the AC1-9/
peptide:MHC complex [24].
These data suggested that T cells from MBPb TCR transgenic
mice bearing one of only two different TCRs could respond to the
Ac1-11/I-Au complex. We were concerned, however, that other T
cells expressing different TCRs might have been lost during the
extended culturing of these cells. Therefore, we generated a new
set of hybridomas following a single stimulation of total lymph
nodes cells harvested from the MBPb TCR mice. The hybridomas
were screened with our panel of 24 Va-specific primers, as
described above. cDNA was generated from approximately 20
Va2
+ and Va2
2 clones, PCR amplified and sequenced. Once
again, we were only able to identify the same two TCRs.
Therefore, under these conditions, only T cells expressing one of
the two different TCRs responded to the Ac1-11 peptide
presented by I-A
u APCs. Importantly, the Va6-Ja13 TCR, which
we named the OVab TCR, responded less well to this antigen
(Fig. 1B and data not shown) and, therefore, can be considered a
functionally lower affinity TCR.
Inefficient positive selection of thymocytes expressing
the low affinity OVab TCR
To analyze the in vivo function of T cells expressing the low
affinity OVab TCR, we generated TCR transgenic mice. The
original MBP Ac1-11 specific transgenic mice (MBPab) were
generated as single-chain transgenics (TCRa and TCRb were not
coinjected). Therefore, it was only necessary for us to construct the
OVa TCR transgene. A 650 bp fragment containing the Va6-
Ja13 gene segment was generated by PCR of DNA from one of
the hybridomas described above. The PCR product was cloned,
sequenced and then transferred into the ,20 kb pTa cassette
vector [20]. This vector contains a TCR Va promoter and the
complete TCR Ca gene, including the Ca enhancer and LCR.
Overall, this transgene vector is very similar to the cosmid vector
used for generating the MBPa transgene [14] and, therefore, it is
expected that the two transgenic constructs should behave
similarly in vivo. The purified transgene was microinjected into
F1 blastocysts obtained from B10.PL x C57Bl/6 female mice.
Two founder transgenic mice were identified and backcrossed
to B10.PL mice that carried the transgene for the MBPb TCR
chain. The phenotype of the two founder lines was nearly identical
Figure 1. Analysis of lymphocytes from MBPb transgenic mice
cultured with the AC1-11 peptide. Total lymphocytes from MBPb-
only transgenic mice were bulk cultured with the MBP-derived AC1-11
peptide. Several additional rounds of activation were done by culturing
with T cell depleted B10.PL splenocytes loaded with the AC1-11
peptide. FACS was carried out seven days after the final activation. (A)
Nearly all remaining cells were CD4
+ and expressed the transgene-
encoded Vb8 TCRb chain. Across several experiments, approximately
30% of the T cells were not Va2 positive. (B) The Va2
+ and Va2
2 T cells
were sorted and then stimulated by the addition of irradiated, T cell
depleted B10.PL splenocytes and titrated amounts of the AC1-11
peptide. Cells were pulsed with 3[H]thymidine after 48 hours and
harvested after a total of 72 hours. Approximately 5610
4 T cells and
1610
5 APCs were used per well. Assays were carried out in triplicate
and averaged. Results shown are representative of three independent
experiments. (C) Predicted amino acid sequence of the CDR3a region of
the Va6 (TRAV6-7/DV9*02) – Ja13 (TRAJ13*01) TCR cloned from the
Va2
2 population. Gene nomeclature based on the IMTG Marie-Paule
convention [46].
doi:10.1371/journal.pone.0017702.g001
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the transgenes for both the OVa TCR chain and the MBPb TCR
chain as well as homozygous for the H-2u MHC haplotype were
selected for analysis. Negative littermates, MBPb TCR only
littermates and age matched MBPab TCR transgenic mice were
used for controls. In addition to the direct injection into B10.PL x
C57Bl/6 F1 blastocysts, mice were backcrossed to B10.PL for at
least five generations.
The increased percentage (consistently over 30%) of CD4 single
positive (CD4SP) thymocytes expressing the MBPab TCR as
compared to nontransgenic littermates or littermates carrying only
the MBPb TCR chain indicated strong positive selection of this
TCR (Fig. 2A). In sharp contrast, thymocytes from mice
expressing the OVab TCR had little obvious skewing towards
the CD4 lineage (Fig. 2A). Indeed, the percentage of cells in the
various CD4 versus CD8 quadrants identified by FACS was very
similar to what was seen for MBPb TCR only and wildtype mice
(Fig. 2A). Overall cellularity of the thymuses from the OVab TCR
and MBPab TCR mice was similar, although, as with all TCRab
transgenic mice, the cellularity was reduced as compared to TCRb
only and wild type mice. Finally, in the periphery, in sharp
contrast with the ,15:1 CD4:CD8 ratio of MBP T cells (Fig. 2),
the CD4:CD8 ratio of T cells from the OVab TCR mice was only
,2:1, similar to the MBPb only TCR transgenic mice.
Most likely the failure of the MHC class II restricted OVab
TCR to increase overall percentages of CD4SP thymocytes and
CD4
+ T cells was due to poor positive selection. Inefficient positive
selection has been shown to result in the replacement of transgenic
TCRa chains with a chains from the endogenous locus [25,26]. It
has also been shown that a rearranged VaJa gene segment that
was introduced into the genomic Ja region was removed by
secondary TCRa rearrangements when the selecting MHC allele
was not present [27,28]. We were not able to directly measure the
loss of cell surface expression of the transgene encoded TCRa
chain since a mAb specific for this Va gene segment does not exist
and a published I-A
u:Ac1-11 tetramer was no longer available.
Therefore, to estimate the loss of the transgene-encoded TCRa,
Figure 2. Development of OVab TCR expressing thymocytes.
The strong skewing of thymocytes expressing the high affinity MBPab
TCR towards the CD4 lineage is not seen in OVabTCR expressing mice.
Expression of only the MBPb chain does not markedly alter T cell
development. (A) Single cell suspensions of thymocytes (top) and
lymph node cells (bottom) from OVab, MBPab, MBPb transgenic and
transgene negative mice were stained with antibodies against CD4, CD8
and TCR Cb. Only TCR Cb
+ cells are shown in the lymph node cell plots.
The number indicates the percent of cells in the quadrant. Only subtle
variations in the percent of cells within each quadrant were noted
during repeat experiments. (B) CD4 SP thymocytes from OVab TCR
transgenic mice express a high percentage of endogenous TCRa chains,
whereas MBPab TCR transgenic mice predominantly express the
transgene encoded Va2 chain. Single cell suspensions of thymocytes
from the indicated mouse strain were stained with antibodies against
CD4, CD8 and individually with each of the four available TCR Va
specific antibodies. The percent of cells within the CD4 single positive
population expressing each of the Vas is shown. More than 1610
6
events were collected per sample. One of two experiments is shown.
Greater than 98% of T cells in the OVab, MBPab and MBPb mice
expressed the transgene encoded Vb8.2 TCR. (C) Increased levels of
proliferation in response to the Ac1-11 peptide indicate a substantial
number of antigen specific T cells develop in the OVab mice. CD4 T cells
were enriched by negative selection. Double cultures were set up with
2.5610
4 CD4
+ T cells and 1610
5 T cell depleted, irradiated B10.PL
splenocytes plus the indicated amount of the MBP Ac1-11 peptide.
Assays were pulsed with 3[H]thymidine after 48 hours and harvested
after an additional 24 hours. Each condition was set up in triplicate and
data was averaged. One example of three experiments is shown.
doi:10.1371/journal.pone.0017702.g002
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TCR and wild type B10.PL mice with anti-TCR Va2, Va3.2,
Va8 and Va11 mAbs (Fig. 2B). In the MBPab TCR mice, over
97% of the CD4SP thymocytes expressed the transgene encoded
Va2 TCR (Fig. 2B), while the other Vas were hardly detectable.
In contrast, CD4SP thymocytes from the OVab TCR mice
(Fig. 2B) expressed high levels of all four TCR a chains in CD4
single positive thymocytes (9.3% Va2, 2.7% Va3.2, 2.2% Va8 and
7.9% Va11) (Fig. 2B). Indeed, the percentage of CD4SP
thymocytes expressing each endogenous Va was similar to what
was seen in MBPb TCR only and wild type B10.PL mice (Fig. 2B).
These data strongly suggest that that thymocytes carrying the
transgene expressing the low-affinity OVab TCR commonly
revised their TCR and, as a consequence, expressed endogenously
rearranged TCRa chains.
To directly test for the presence of AC1-11 specific T cells in the
OVab TCR mice, we purified CD4 T cells from the spleen and
lymph nodes of OVab TCR, MBPab TCR, MBPb TCR only
transgenic mice as well as from control transgene negative mice. T
cell proliferation assays were carried out by incubating CD4
+ T
cells with irradiated B10.PL splenocytes plus titrated amounts of
the AC1-11 peptide (Fig. 2C). As anticipated, purified MBPab
TCR T cells proliferated strongly, while wild type CD4 T cells did
not respond at all. MBPb TCR CD4 T cells also responded due to
a relatively high frequency of antigen specific T cells, as previously
published [22]. The CD4
+ OVab T cells clearly responded much
more vigorously than the MBPb TCR only T cells. Therefore,
although we did not observe strong skewing towards the CD4
lineage in mice carrying the OVab TCR transgenes, we were able
to detect a relatively strong antigen-specific T cell response.
Selection of MBPab TCR and OVab TCR expressing
thymocytes in the absence of endogenous TCRs
To exclude the T cells bearing endogenous TCRs, we generated
B10.PL, RAG1 deficient mice carrying the transgenes for either
the OVab TCR or the MBPab TCR. Similar to the data from the
RAG sufficient mice, most MBPab TCR expressing thymocytes
(Fig. 3A) were found to be at the CD4SP positive stage or had
downregulated CD4 and CD8 and were likely on their way
towards becoming CD4SP [22,29]. In contrast, over 85% of the
OVab TCR expressing thymocytes were found to be at the DP
stage, with only 7% progressing to the mature CD4SP stage.
Although the TCR is MHCII restricted, a small number of CD8
+
cells are seen in both mice. Such ‘‘mismatched’’ cells are
commonly found in the TCR transgenic mice.
Productive interactions of TCRs expressed by developing
thymocytes with self-MHC:self-peptide complexes can be mea-
sured by staining for the upregulation of the early activation
marker CD69 [29]. The minimal upregulation of CD69 on double
positive (DP) thymocytes expressing the OVab TCR, as compared
to the MBPab TCR, confirms that OVab TCR expressing
thymocytes are very poorly positively selected (Fig. 3B). These data
also ruled out increased negative selection of the OVab TCR
expressing thymocytes since negative selection would also result in
increased CD69 levels.
Despite poor positive selection, OVab TCR transgenic T cells
accumulate in the periphery (Fig. 3C) in RAG1 deficient mice.
Similar to the MBPab TCR T cells, nearly all of the OVab TCR
expressing T cells are found within the CD4
+ compartment.
Unlike the CD4:CD8 ratio of the peripheral T cells from OVab
TCR B10.PL mice, which was about 2:1, the OVab TCR
Rag1
2/2 had a CD4:CD8 ratio greater than 10:1, similar to what
was seen in MBPab TCR Rag1
2/2 mice (Fig. 3C). Spleen and
lymph node cellularity was, on average, higher in the MBPab
TCR RAG1 deficient mice.
OVab TCR T cells have a lower affinity than MBPab TCR T
cells for the I-A
u:Ac1-11 complex
The original T cell cultures and the hybridomas generated from
these T cells both showed that the OVab TCR had a functionally
lower affinity for the I-A
u:Ac1-11 complex than the MBPab TCR.
Before evaluating in vivo function, it was necessary to determine if
the naı ¨ve T cells collected from the two TCR transgenic mice
retained this functional difference. Furthermore, by using a
blocking mAb it was possible to directly compare the relative
avidities of the two TCRs [21].
CD4 T cells from OVab and MBPab TCR transgenic
RAG1
2/2 mice were purified by negative selection and then
challenged with irradiated I-A
u splenocytes loaded with titrated
Figure 3. Thymocytes expressing the OVab TCR are poorly
positively selected even in the absence of endogenous TCRs.
(A) As compared to thymocytes expressing the high affinity MPBab
TCR, the OVab TCR is very inefficiently positively selected, which is
reflected in a much lower percentage of CD4SP thymocytes. (B)O V ab
TCR transgenic double positive (DP) thymocytes have a minimal
upregulaton of CD69, which is an indicator of productive TCR-MHC
interactions. (C) FACS analysis of lymph node cells shows that, despite
poor positive selection, CD4 T cells accumulate in the OVab TCR
transgenic mouse.
doi:10.1371/journal.pone.0017702.g003
TCR Affinity and EAE
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original T cell lines as well as with the hybridomas, naı ¨ve OVab T
cells respond much less well to the I-A
u:Ac1-11 complex than the
MBP TCR expressing T cells (Fig. 4A). To test the relative affinity
of the two TCRs for I-A
u:Ac1-11 complex, we first incubated
purified T cells with different doses of F23.1 [30], an anti-Vb8.2
mAb that we have previously shown does not cause activation of T
cells at the concentrations used for these experiments [21]. We
then examined the response to titrated doses of peptide. As can be
seen in Fig. 4A, 1 mg/ml of F23.1 completely blocked the response
of T cells from both mice. At a 10-fold lower dose of blocking
mAb, however, MBPab T cells respond strongly, while OVab T
cells are still completely blocked. We next used titrated amounts of
the blocking mAb, while keeping the peptide concentration
constant (Fig. 4B). Again, the response of T cells from the OVab
mouse line was blocked by much less mAb. Since the absolute level
of proliferation greatly differed between the two T cell types, we
also expressed the data as the percent of the maximum response
(Fig. 4C). Here it is clear that even just 10ngs of the anti-Vb8.2
mAb is sufficient to partially block the response of the OVab T
cells, whereas the MBPab T cells are not affected. Together these
data show that the affinity of the OVab TCR for the I-A
u:Ac1-11
complex is substantially less than the affinity of the MBP TCR for
the same ligand.
Development of spontaneous EAE in mice transgenic for
low-affinity MBP-specific TCR
RAG-sufficient mice carrying the transgenes for the OVab TCR
or the MBPab TCR were monitored for a period up to twelve
months. The incidence of spontaneous EAE was recorded from the
onset ofobvioushindleg paraparesis(gaitdisturbance). Theanimals
weresacrificed when full hind leg paralysis was observed. Consistent
with reported results, approximately 40% (4 of 10 mice, Fig. 5 A,B)
of MBPab TCR mice developed EAE, with an average onset of
approximately 11 weeks after birth [14,31]. In contrast, only one
OVab mouse was observed to develop EAE (Fig. 5 A,B). Onset of
the disease in this mouse occurred 16 weeks after birth. A group of
nine OVab TCR mice was monitored for a total of twelve months
and more than 50 mice were monitored for a shorter period of time
(,6 months). Of this group, only one additional mouse (12 weeks
old) showed any overt signs of the disease.
The greatly reduced frequency of EAE in the OVab TCR mice
is most likely due to one, or a combination of, three factors. First,
the lower frequency of OVab TCR T cells as compared to
Figure 4. The relative affinity of the OVab and MBPab TCRs.
Antibody blocking studies show that the OVab TCR is of much lower
affinity for the I-A
u:Ac1-11 peptide ligand as compared to the MBPab
TCR. (A) Purified CD4
+ T cells from MBPab TCR RAG1
2/2 and OVab TCR
RAG1
2/2 mice were incubated with the indicated amount of antibody
against Vb8 (F23.1) and then challenged with titrated amounts of the
Ac1-11 peptide presenting by B10.PL APCs. (B) Purified T cells were
activated with 3uM Ac1-11, presented by B10.PL APCS, in the presence
of titrated amounts of blocking antibody. Assays were pulsed after
48 hours and harvested at 72 hours. Each condition was done in
triplicate and the data was averaged. One representative experiment of
three is shown. (C) For clarity, the data from (B) are presented as the
percent of the maximal response of the T cells without the blocking
antibody.
doi:10.1371/journal.pone.0017702.g004
Figure 5. Development of spontaneous EAE in TCR transgenic
mice. (A) RAG1 deficient mice were monitored for twelve months for
overt signs of EAE (hind leg paraparesis). The day of the onset of EAE in
individual mice is indicated on the chart. (B) More than 60% of MBPab
mice and nearly all OVab TCR mice remained healthy throughout the
course of the study, whereas 100% of the TCR transgenic RAG1
deficient became sick. Onset of disease was at an average of eleven
weeks of age in all three susceptible mice.
doi:10.1371/journal.pone.0017702.g005
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OVab TCR may make it inherently less encephalitogenic; or
third, regulatory T cells (presumably CD4
+CD25
+ T cells) might
be more effective at controlling the lower affinity OVab T cells.
We sought to differentiate between these possibilities by studying
the RAG1 deficient MBPab and OVab TCR transgenic mice.
It has been shown that if all endogenous TCR expression is
removed from a mouse line carrying the transgenes for a different
AC1-11/I-Au specific TCR, 100% of the mice develop EAE [15].
This result is due, at least in part, to the removal of residual
CD4
+CD25
+ Treg cells that develop due to the expression of non-
transgene encoded TCRs [16]. Therefore, we monitored RAG1
deficient mice carrying the transgenes for the high affinity MBPab
TCR for signs of EAE. In contrast to RAG1 sufficient MBPab
TCR mice, 100% of the MBPab TCR, RAG1 deficient mice (24
mice) developed EAE (Fig. 5 A, B). Interestingly, the RAG1
deficient mice developed EAE at the same age (11 weeks) as their
RAG1 sufficient counterparts (Fig. 5A, Ref. [14,31]. We also
evaluated our RAG1 deficient OVab TCR transgenic mice. In
sharp contrast to what we found in the OVab RAG1 sufficient
mice, 100% (25/25 mice) of the OVab RAG1 deficient mice
developed EAE (Fig. 5A, B). Remarkably, the age that the mice
developed the disease was, on average, nearly identical to both the
MBPab RAG1 sufficient and MBPab RAG1 deficient mice
(Fig. 5A, B).
Discussion
The underlying reasons for the onset of T cell mediated
autoimmune diseases are complex and involve a variety of genetic
and environmental factors. The presence of self-peptide:self-MHC
specific T cells is, however, clearly essential. In general, a minimal
affinity between self-MHC:self-peptide complexes and the TCR
appears to be an important factor for the function T cells [32]. T
cells that initiate autoimmune diseases, however, presumably have
avidities for self-ligands that are closer to pathogen-derived antigen
specific responses [33].
Autoimmunity is commonly thought to require high affinity
‘‘driver’’ T cell clones that initiate disease and cause inflammation
[34]. This inflammation results in a DTH-like response that
recruits macrophages and other non-specific T cells. The damage
caused by the inflammation can also lead to epitope spreading,
resulting in the activation of T cells specific for epitopes distinct
from the disease-causing epitope. This secondary response, which
appears to occur within the CNS, rather than peripheral sites
[11,35], may involve lower affinity T cell clones [36]. Self-antigen
specific driver clones, therefore, must be present in all mouse
strains that are susceptible to EAE. Nonetheless, EAE typically
does not occur spontaneously; rather it must be stimulated by
various immunization protocols. Even TCR transgenic mice that
have nearly clonal populations of high affinity self-reactive T cells
are completely [15] or at least partially [14] protected from the
onset of spontaneous EAE. It has been previously shown for one of
these models that when the TCR transgenes were introduced into
mice deficient for RAG1 expression, EAE developed spontane-
ously [15]. Therefore, a minor population of lymphocytes that
required RAG1 for development played a critical role in
suppressing disease. Later, the suppressor cells were definitively
determined to be CD4
+ T cells expressing non-transgene encoded
TCRs [16].
Our studies of a low-affinity MBP AC1-11 peptide/I-A
u specific
TCR-transgenic model were designed to determine if the affinity
of the TCR-MHC/peptide interaction played a role in the
pathogenesis of EAE. We first characterized antigen specific T
cells from mice carrying only the MBP TCRb chain. Interestingly,
our analysis revealed that the TCR repertoire of the AC1-11 MBP
peptide reactive T cells in these mice was limited to only two
different TCRs. These data imply that central tolerance is highly
efficient at removing all other TCRs reactive for this ligand, but
for unknown reasons, fails to remove thymocytes expressing these
two TCRs. This TCRa chain was used to generate a new TCR
transgenic mouse model, which was compared to an existing
mouse model that expresses a related high affinity TCR.
It is not known how disease causing, self-reactive T cells escape
intrathymic negative selection [37]. One possibility is that
thymocytes expressing TCRs that have very high avidities for
self-antigens actually are deleted due to the ectopic expression of
peripheral ‘‘tissue-specific’’ proteins in the thymus [38,39,40,41].
Indeed, it has previously been shown that mice lacking the last five
exons of MBP (shiverer mice) mount T cell responses to additional
MBP-derived epitopes [42,43]. These data demonstrated that
thymic expression of the MBP is directly responsible for tolerance
of at least some MBP-reactive thymocytes. Tissue specific antigens,
however, may be expressed at low levels and, therefore, may not
be efficient at negative selection of lower affinity self-reactive
clones [44]. A variant on this idea is that the form of the self-
antigen expressed in the thymus is somehow distinct from the
peripherally expressed antigen [11]. In the case of the shiverer
mice, T cell responses against the AC1-11 MBP derived peptide in
shiverer mice were similar to those in wild type mice suggesting
that the relatively unstable I-A
u:Ac1-11 complex is not efficient at
driving clonal deletion [42,43].
Whatever the exact mechanism of clonal escape might be, it was
reasonable to hypothesize that thymocytes expressing the lower
affinity OVab TCR would develop at least as efficiently those
expressing the as the higher affinity MBPab TCR. Indeed, the
lower affinity for self-antigen would arguably make the OVab
TCR thymocytes less susceptible to clonal deletion. We found,
however, that the low affinity OVab TCR was actually very
poorly positively selected. There was no indication of negative
selection (i.e. reduced cellularity, upregulation of CD69, etc.) in
either mouse. Therefore, in contrast to finding that aberrant
negative selection plays a significant role in allowing the escape of
disease causing T cells, we find that positive selection is a major
contributor. In other words, in our model system, high affinity,
self-reactive T cells are efficiently positively selected, whereas, low
affinity, less ‘‘dangerous’’ clones, fall by the wayside. This
difference in positive selection may also account for the four-fold
excess of high affinity T cell clones that we consistently find in the
TCRb only mice.
Consistent with previous studies [14,31], in our analysis, we also
found that ,40% of mice carrying the transgenes for the high
affinity MBPab TCR spontaneously developed EAE at approx-
imately eleven weeks of age. This level of penentrance is consistent
with what we have seen over several years of maintaining this
mouse strain. Of the nine OVab TCR mice that we monitored for
the complete twelve months, only one mouse developed EAE.
Overall, approximately fifty OVab TCR mice were produced and
were monitored for up to six months, with only one additional
mouse showing clear signs of paralysis, which occurred at 12
weeks. The minimal number of sick OVab TCR mice is due
either to the reduced affinity of the TCR and/or due to the
reduced numbers/percentage of MBP specific T cells. Clearly the
total number of potentially encephalitogenic T cells in the OVab
TCR mice far exceeds what can be found in a wild type mouse,
but, nonetheless, it is several fold fewer than the more disease
prone MBPab TCR transgenic mice. Eliminating all endogenous
TCRs by breeding to RAG1 deficient mice, however, demon-
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kept in check by the presence of RAG-dependent regulatory cells.
Based on previous work, these regulatory cells are, at least in part,
CD25
+CD4
+ Tregs [16,17]. These data, therefore, suggest one of
two possibilities, which are not exclusive. First, the absolute ratio of
Tregs to self-reactive T cells may be critical, with relatively subtle
alterations resulting in disease. Alternatively, Tregs may be far
more efficient at controlling self-reactive T cells with lower affinity
TCRs. We anticipate that cell transfer studies will allow us to
distinguish between these two mechanisms.
Rather surprisingly, the onset of EAE for the MBPab TCR
mice on a wild type background and both the MBPab TCR and
OVab TCR mice on a RAG1 deficient background was nearly
identical, with a mean of eleven weeks. Even the two OVab TCR
RAG1 sufficient mice in which disease was observed became sick
around this timeframe (12 and 16 weeks). These data suggest that
some initiating event, perhaps release of myelin basic protein due
to apoptosis of nerve cells, reproducibly occurs soon after the mice
enter adulthood. Perhaps this is related to the finding that self-
reactive T cells contribute to neurogenesis [45]. Importantly, if
RAG dependent cells, such as Tregs, are present during this
‘‘window of opportunity’’, they are capable of preventing
autoimmune disease.
Overall, our analysis of high and low affinity MBP Ac1-11
specific T cells reveals several important aspects concerning the
onset of the autoimmune disease, EAE. First, the frequency of
different clonotypes that are capable of recognizing the dominant
Ac1-11 epitope appears to be very limited. Second, positive
selection, rather than negative selection, appears to have a major
impact on the frequency of different clonotypes. Third, regulatory
cells appear to be very efficient at controlling self-reactive T cells
expressing a low affinity TCR. And finally, potentially encepha-
litogenic T cells appear to have relatively short window of
opportunity to cause disease. Intriguingly, if regulatory cells are
present during this window of opportunity, which is around eleven
weeks after birth, more often than not encephalitogenic T cell
responses are suppressed and this suppression lasts a lifetime.
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